NK cells contribute to early defense against viruses through their innate abilities, which include recognition of PAMPs and inflammatory signals such as cytokines or chemokines, recognition and killing of infected cells through activation of interaction with surface receptors. Moreover, they support adaptive responses through CD16-triggered Ab-dependent mechanisms and DC editing. Their fundamental role in the antiviral response has been revealed in NK cell-deficient patients suffering from severe herpesvirus infections.
Remarkably, these infections, which often occur as primary infections early in life, can be effectively cleared by NK, T, and B cells in healthy hosts. However, herpesviruses create a complex balance with the host immune system through their latency cycle, moving between immune control and viral reactivation. This lifelong problem has contributed to the development of numerous evasion mechanisms in herpesviruses, many of which are aimed at evading NK cell surveillance from viral reactivation rather than primary infections. This delicate balance can be altered in healthy people, promoting reactivation of the virus, and, more often, in people with weakened immune systems.PROTOCOL OF HSV1-2 TREATMENT:NEW PROTOCOL OF HSV TREATMENT
Overview of the major activating receptors regulating Nk-mediated recognition and effector responses to herpes virus.
The main mechanisms by which NK cells can recognize and eliminate virus-infected cells include the use of activation of receptors for cellular ligands, often overexpressed during infection, activation of receptors for viral-derived ligands, activation of receptors, i.e. , NKG2C and aKIR, recognizing virus-modified HLA-I molecules, and CD16-mediated antibody-dependent cellular cytotoxicity. Almost all of these mechanisms can be applied to NK cells in the fight against herpes virus.
The importance of certain activating receptors in herpes virus clearance has been indirectly revealed by numerous proteins encoded by various herpes viruses that aim to limit the function of activating receptors, in most cases by downregulating the corresponding cellular ligands on infected cells. NCR NKp30 is also involved in the recognition and killing of cells infected with CMV and HHV6. Its involvement is again suggested by viral evasion mechanisms that downregulate B7-H6, the major cellular ligand of NKp30. In addition, NKs themselves are the target of a protein that, by binding to this NCR, can induce its dissociation from the signaling molecule CD3ζ, thereby inhibiting NK-mediated killing of CMV-infected fibroblasts and dendritic cells. NK receptors are specifically involved in the recognition/destruction of herpes virus-infected cells.
The involvement of 2B4 is critical for NK-mediated killing of EBV-infected B cells. Indeed, CD48-rich B cells represent the preferred target of this herpes virus. A role for 2B4 has in fact been identified in the severe sequelae of primary EBV infection in individuals suffering from X-linked lymphoproliferative disorder, a congenital immunodeficiency in which the SAP is absent or damaged , resulting in inhibitory signals from 2B4 impairing NK-mediated clearance of B-EBV. Interestingly, NK cells can effectively respond to EBV-infected B cells early in the lytic cycle, and NK -mediated killing also includes NKG2D and DNAM-1.
Overall, in most cases, the activating receptors described above allow NK cells to kill infected cells by recognizing cellular ligands. Another major mechanism used by NK cells to control both primary viral infections, when adaptive immunity is already established, and secondary reactivations ( subclinical or clinical), is based on the activation of the CD16 receptor with low affinity for immunoglobulin Fc. fragment. When interacting with CD16, NK cells can effectively kill opsonized infected cells through ADCC.
The relevance of this mechanism in providing protection against herpes virus is emphasized by severe EBV and VZV infections associated with dysfunctional mutated CD16.
NK cells may make an important contribution to early viral defense not only through cytolytic activity against infected cells, but also through their ability to sense pathogens through toll-like receptors). NK cells express various functional TLRs, among which TLR2, TLR3 and TLR9 appear to be primarily involved in the recognition of pathogen-associated molecular patterns (PAMPs) derived from herpes viruses, such as double-stranded viral nucleic acids or structural proteins
In particular, NK cells can directly recognize the envelope glycoproteins of CMV and HSV virions through TLR2. When TLR2 is engaged, NK cells are activated and produce IFN-γ, which further promotes the antiviral immune response. Indeed, NK cells have been found in herpetic lesions in close contact with CD4 T cells, possibly contributing directly to the generation of adaptive responses.
Thus, in a scenario where NK cells are recruited to sites of viral infection, their effector function (e.g. , cytotoxicity, IFN-γ, and chemokine production) may be enhanced by the combined effects of microbial products and cytokines available in the inflammatory environment, such as IL-12 or IL-18. In this context, NK cells activated by TLRs and/or cytokines can reciprocally interact with other immune cells responding to the same PAMPs via TLRs, such as DCs or macrophages (Figure 1D However, it should be noted that TLR-mediated sensing of viral PAMPs by NK -cells have not yet been conclusively established, similar to the contribution of TLRs on DCs and macrophages in response to NK cells.
As mentioned above, major defects in NK cell function against human herpes viruses have been described and overwhelmingly occur during primary infections, which can be fatal upon first exposure to the virus. Stem cells for treatment herpes virus https://mediland.clinic/2021/01/27/stem-cell-treatment-for-herpes-virus/
These cases represent a very limited proportion of clinical syndromes caused by herpes virus, since most primary infections are controlled by the immune system, often as asymptomatic infections, and the vast majority of patients enter a period of latency without further clinical reactivation in >70% of infected subjects. absence of secondary immunodeficiencies (for example, HIV infection, transplantation, immunosuppression).For this reason, most NK cell evasion mechanisms are less relevant during the acute phase of primary infection.
Herpesvirus latency has long been considered a period of antigenic eclipse of the immune system, while reactivation with clinical symptoms represents a possible failure of the immune system to control viral latency. Most virus-induced NK cell (and/or T cell) evasion strategies can be active during clinical escape or reactivation phases.
However, this view needs to be carefully re-evaluated in view of the overwhelming amount of data showing that emergence from latency or viral reactivation occurs commonly for all herpes viruses in infected hosts at the subclinical level. Thus, clinically latent herpes virus infection actually has a continuous component of persistent immune stimulation behind account of viral replication in part of the pool of infected cells. In this context, viral evasion mechanisms are likely to operate continuously and are quantitatively more frequent and relevant than during primary infection.
OUR APPROACH OF HERPES TREATMENT READ ON THIS PAGE:
Stem Cell Treatment for Herpes Virus: Regenerative & Immune-Modulating Therapy
Taking into account these considerations, as well as the participation of persistent herpesvirus infection in the modulation of autoimmune, allergic, atopic and atherosclerotic phenomena, herpesviruses and the host from an evolutionary-ecological point of view can be considered as co-evolved symbionts that are in an evolutionary relationship.
We use NK cells from bone marrow and umbilical cord lymph nodes. NK cells are nonspecific immune cells that can kill the herpes virus. After all, patients with the herpes virus usually do not have NK cells or have fewer of them than they need.
Some Testimonials after therapy: Patients Reviews and MAIN INFORMATION ABOUT IMPROVEMETS Remission After Immune-Modulating Therapy
CONTACT OUR DOCTOR
Hello interested to know more about this treatment on offer as I suffer from hsv1 genital and would be potentially interested in this thank you
Basic therapy lasts 4-5 days (depending on how long the virus has been in the body). The therapy activates the innate immune system cells NK and T cells, which find the virus and neutralize it, meaning it becomes inactive.
How do I get this treatment and how much does it cost?
You can contact us using the contact form on the website or by phone (messengers). Based on your medical history, an individual treatment plan will be developed for you.